Form 4: Tempest Therapeutics CEO Acquires 550,000 Stock Options
SEC Form 4 Filing
Stephen R. Brady, President and CEO of Tempest Therapeutics, Inc., acquired 550,000 stock options on January 2, 2025, according to a Form 4 filing with the SEC.
Summary
- Stephen R. Brady, the President and CEO of Tempest Therapeutics, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on January 2, 2025.
- Brady acquired 550,000 employee stock options with an exercise price of $0.86.
- These options vest in 48 equal monthly installments starting from January 2, 2025, contingent upon continued service.
- The options expire on January 1, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation practice. The option grant itself doesn't inherently indicate positive or negative performance, but rather incentivizes future performance.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Future Outlook
The vesting schedule of the options suggests a long-term commitment from the CEO to the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the biotech industry to incentivize performance.
- Comparing the size and vesting schedule of these options to those of CEOs at similarly sized biotech companies (e.g., those with similar market capitalization and stage of drug development) would provide context on whether this grant is typical.
- Companies like Madrigal Pharmaceuticals, Viking Therapeutics, or Ardelyx could serve as benchmarks for comparison.
Stakeholder Impact
- Shareholders may view this as a positive sign, aligning the CEO's interests with the company's long-term success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option acquisition and start of vesting period. |
| 01/06/2025 | Date of the Form 4 filing. |
| 01/01/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.